NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $128 | -76.6% | 183,836 | -24.4% | 0.00% | -100.0% |
| Q4 2022 | $548 | -99.9% | 243,120 | +1.3% | 0.00% | -50.0% |
| Q3 2022 | $765,000 | +7.3% | 239,973 | +27.7% | 0.00% | 0.0% |
| Q2 2022 | $713,000 | -19.0% | 187,984 | +18.0% | 0.00% | 0.0% |
| Q1 2022 | $880,000 | -59.1% | 159,303 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $2,152,000 | +37.9% | 159,303 | +84.3% | 0.00% | 0.0% |
| Q3 2021 | $1,560,000 | +28.6% | 86,429 | +22.2% | 0.00% | +33.3% |
| Q2 2021 | $1,213,000 | -13.9% | 70,735 | +0.2% | 0.00% | 0.0% |
| Q1 2021 | $1,409,000 | +11.8% | 70,567 | -4.9% | 0.00% | +50.0% |
| Q4 2020 | $1,260,000 | -10.6% | 74,202 | -12.8% | 0.00% | -33.3% |
| Q3 2020 | $1,410,000 | -32.0% | 85,118 | -5.1% | 0.00% | -40.0% |
| Q2 2020 | $2,075,000 | +27.5% | 89,651 | -1.8% | 0.01% | +25.0% |
| Q1 2020 | $1,628,000 | -10.3% | 91,278 | +7.7% | 0.00% | 0.0% |
| Q4 2019 | $1,815,000 | +47.2% | 84,759 | +25.4% | 0.00% | +33.3% |
| Q3 2019 | $1,233,000 | -48.8% | 67,596 | -0.2% | 0.00% | -40.0% |
| Q2 2019 | $2,408,000 | +3.3% | 67,730 | -2.6% | 0.01% | -16.7% |
| Q1 2019 | $2,332,000 | -8.9% | 69,529 | -15.5% | 0.01% | -14.3% |
| Q4 2018 | $2,559,000 | -48.4% | 82,254 | +1.1% | 0.01% | -41.7% |
| Q3 2018 | $4,963,000 | +28.1% | 81,371 | +2.5% | 0.01% | +33.3% |
| Q2 2018 | $3,874,000 | -14.1% | 79,355 | +87.1% | 0.01% | -18.2% |
| Q1 2018 | $4,512,000 | -63.1% | 42,412 | -79.3% | 0.01% | -62.1% |
| Q4 2017 | $12,228,000 | +142.4% | 204,863 | -3.9% | 0.03% | +123.1% |
| Q3 2017 | $5,045,000 | +15.7% | 213,075 | -4.5% | 0.01% | +8.3% |
| Q2 2017 | $4,361,000 | -13.1% | 223,215 | +4.3% | 0.01% | -14.3% |
| Q1 2017 | $5,019,000 | +104.4% | 213,944 | +7.0% | 0.01% | +100.0% |
| Q4 2016 | $2,455,000 | -61.1% | 199,988 | -45.6% | 0.01% | -22.2% |
| Q3 2016 | $6,306,000 | +151.8% | 367,364 | +108.6% | 0.01% | +12.5% |
| Q2 2016 | $2,504,000 | +1152.0% | 176,113 | +1106.7% | 0.01% | +700.0% |
| Q1 2016 | $200,000 | +20.5% | 14,594 | +47.9% | 0.00% | 0.0% |
| Q4 2015 | $166,000 | +53.7% | 9,870 | 0.0% | 0.00% | – |
| Q3 2015 | $108,000 | -12.2% | 9,870 | 0.0% | 0.00% | – |
| Q2 2015 | $123,000 | +13.9% | 9,870 | 0.0% | 0.00% | – |
| Q1 2015 | $108,000 | -29.4% | 9,870 | 0.0% | 0.00% | -100.0% |
| Q4 2014 | $153,000 | +27.5% | 9,870 | 0.0% | 0.00% | – |
| Q3 2014 | $120,000 | -4.8% | 9,870 | 0.0% | 0.00% | – |
| Q2 2014 | $126,000 | +5.9% | 9,870 | 0.0% | 0.00% | – |
| Q1 2014 | $119,000 | +120.4% | 9,870 | +107.6% | 0.00% | – |
| Q4 2013 | $54,000 | – | 4,755 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |